FDA grants Priority Review for Padcev plus Keytruda in muscle-invasive bladder cancer, showing improved survival and reduced ...
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in ...
At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...
Randomization enrolled 1841 systemic-therapy–naïve patients within 12 weeks post-surgery to 1 year pembrolizumab plus daily belzutifan or placebo. Disease-free survival improved despite unreached ...
Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it ...
In India, Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results